Zynerba Pharmaceuticals, Inc.
TREATMENT OF AUTISM WITH CANNABIDIOL

Last updated:

Abstract:

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome ASD are treated in the subject.

Status:
Application
Type:

Utility

Filling date:

14 May 2019

Issue date:

29 Aug 2019